{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:17Z","timestamp":1786118897251,"version":"build-2736575974"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/icu.0b013e328310da18","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T03:09:39Z","timestamp":1223953779000},"page":"468-478","source":"Crossref","is-referenced-by-count":28,"title":["Medical treatment options for ocular myasthenia gravis"],"prefix":"10.1097","volume":"19","author":[{"given":"Aileen A","family":"Antonio-Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R","family":"Eggenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210206","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1196\/annals.1254.060","article-title":"Treatment principles in the management of autoimmune myasthenia gravis","volume":"993","author":"Richman","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R2-5-20210206","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R3-5-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2007.02038.x","article-title":"Clinical and laboratory-reconfirmed myasthenia gravis: a population-based study","volume":"15","author":"\u0150\u00f6pik","year":"2008","journal-title":"Eur J Neurol"},{"key":"R4-5-20210206","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1196\/annals.1254.054","article-title":"Myasthenia gravis (MG): epidemiological data and prognostic factors","volume":"998","author":"Mantegazza","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/jnnp.2006.100545","article-title":"Clinical and serological study of myasthenia gravis in HuBei Province, China","volume":"78","author":"Zhang","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R6-5-20210206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1212\/WNL.51.1.255","article-title":"Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study.","volume":"51","year":"1998","journal-title":"Neurology"},{"key":"R7-5-20210206","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.65.4.492","article-title":"Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England","volume":"65","author":"Robertson","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-5-20210206","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0404.1999.tb00733.x","article-title":"Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983\u20131992)","volume":"100","author":"Lavrni\u0107","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"R9-5-20210206","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archopht.1959.04220060057010","article-title":"Evaluation of ocular signs and symptoms in myasthenia gravis","volume":"52","author":"Schlezinger","year":"1959","journal-title":"Arch Ophthalmol"},{"key":"R10-5-20210206","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R12-5-20210206","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/01.wnl.0000269665.62498.5c","article-title":"Restoring balance at the neuromuscular junction","volume":"69","author":"Kaminski","year":"2007","journal-title":"Neurology"},{"key":"R13-5-20210206","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1096\/fj.02-0609com","article-title":"The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis","volume":"17","author":"Brenner","year":"2003","journal-title":"FASEB J"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1212\/01.wnl.0000267884.39468.7a","article-title":"Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase","volume":"69","author":"Argov","year":"2007","journal-title":"Neurology"},{"key":"R15-5-20210206","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"R16-5-20210206","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"R17-5-20210206","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1196\/annals.1254.060","article-title":"Treatment principles in the management of autoimmune myasthenia gravis","volume":"998","author":"Richman","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R18-5-20210206","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"R19-5-20210206","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of corticosteroids on ocular myasthenia gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Arch Neurol"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1749-6632.1987.tb51325.x","article-title":"Long-term corticosteroid treatment of myasthenia gravis","volume":"505","author":"Johns","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"R21-5-20210206","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/archneur.64.12.1790","article-title":"Ocular myasthenia gravis treatment. The case against prednisone therapy and thymectomy","volume":"64","author":"Gilbert","year":"2007","journal-title":"Arch Neurol"},{"key":"R22-5-20210206","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/archneur.64.12.1792","article-title":"Immunosuppressive or surgical treatment for ocular myasthenia gravis","volume":"64","author":"Chavis","year":"2007","journal-title":"Arch Neurol"},{"key":"R23-5-20210206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"R24-5-20210206","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces the conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuro-Ophthalmol"},{"key":"R25-5-20210206","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in myasthenia gravis: analysis of adverse effects of 163 patients","volume":"13","author":"Rozsa","year":"2006","journal-title":"Eur J Neurol"},{"key":"R26-5-20210206","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann Neurol"},{"key":"R27-5-20210206","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"R28-5-20210206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"J Neurol Sci"},{"key":"R29-5-20210206","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis: results of the second interim analysis.","volume":"56","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R30-5-20210206","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Ann Neurol"},{"key":"R31-5-20210206","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"R32-5-20210206","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1191\/0961203305LU2109OA","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"R33-5-20210206","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1445-5994.2006.01222.x","article-title":"Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity","volume":"37","author":"Lim","year":"2007","journal-title":"Int Med J"},{"key":"R34-5-20210206","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Merriggioli","year":"2003","journal-title":"Neurology"},{"key":"R35-5-20210206","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.51.3.912-a","article-title":"Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil","volume":"51","author":"Hauser","year":"1998","journal-title":"Neurology"},{"key":"R36-5-20210206","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/1097-4598(200008)23:8<1287::AID-MUS22>3.0.CO;2-L","article-title":"Treatment of myasthenia gravis with mycophenolate mofetil: a case report","volume":"23","author":"Meriggioli","year":"2000","journal-title":"Muscle Nerve"},{"key":"R37-5-20210206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"R38-5-20210206","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","article-title":"Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil","volume":"65","author":"Vernino","year":"2005","journal-title":"Neurology"},{"key":"R39-5-20210206","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"R40-5-20210206","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00415-008-0718-9","article-title":"Mycophenolate mofetil for ocular myasthenia","volume":"255","author":"Chan","year":"2008","journal-title":"J Neurol"},{"key":"R41-5-20210206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of Mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"R42-5-20210206","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of Mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"R44-5-20210206","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"R45-5-20210206","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"R47-5-20210206","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"key":"R48-5-20210206","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1468-1331.2008.02130.x","article-title":"Monitoring treatment with cyclosporine microemulsion in myasthenia gravis","volume":"15","author":"Utsugisawa","year":"2008","journal-title":"Eur J Neurol"},{"key":"R49-5-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"R50-5-20210206","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/S0041-1345(98)01367-0","article-title":"FK-506 (tacrolimus) therapy for an unusual SLE-like disease","volume":"30","author":"Kilian","year":"1998","journal-title":"Transplant Proc"},{"key":"R51-5-20210206","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis: a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"key":"R52-5-20210206","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Musc Nerve"},{"key":"R53-5-20210206","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalized myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R54-5-20210206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporine- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"R55-5-20210206","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"R56-5-20210206","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","article-title":"Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone","volume":"13","author":"Shimojima","year":"2006","journal-title":"J Clin Neurosci"},{"key":"R57-5-20210206","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u2018rebooting\u2019 with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"R58-5-20210206","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","article-title":"High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies","volume":"33","author":"Lin","year":"2006","journal-title":"Musc Nerve"},{"key":"R59-5-20210206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Musc Nerve"},{"key":"R60-5-20210206","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ana.10449","article-title":"\u2018Rebooting\u2019 the immune system with cyclophosphamide: taking risks for a \u2018cure\u2019?","volume":"53","author":"Lewis","year":"2003","journal-title":"Ann Neurol"},{"key":"R61-5-20210206","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"R62-5-20210206","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"R63-5-20210206","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Musc Nerve"},{"key":"R64-5-20210206","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R65-5-20210206","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"R66-5-20210206","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"R67-5-20210206","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology"},{"key":"R68-5-20210206","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaut.2005.01.013","article-title":"Myasthenia gravis patients with low plasma IL-6 and IFN-\u03b3 benefit from etanercept treatment","volume":"24","author":"T\u00fcz\u00fcn","year":"2005","journal-title":"J Autoimmun"},{"key":"R70-5-20210206","first-page":"939","article-title":"Long term effects of plasma exchange in myasthenia gravis: results from a randomized study","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse M\u00e9dicale"},{"key":"R71-5-20210206","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jneuroim.2004.10.002","article-title":"Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy","volume":"159","author":"Psaridi-Linardaki","year":"2005","journal-title":"J Neuroimmunol"},{"key":"R72-5-20210206","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravis","volume":"41","author":"Gadjos","year":"1997","journal-title":"Ann Neurol"},{"key":"R73-5-20210206","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1 g\/kg versus 2 g\/kg: a randomized double blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"R74-5-20210206","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"R75-5-20210206","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.298.2.163","article-title":"Novel therapies target myasthenia gravis","volume":"298","author":"Hampton","year":"2007","journal-title":"JAMA"},{"key":"R76-5-20210206","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","article-title":"Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo","volume":"45","author":"Hepburn","year":"2008","journal-title":"Mol Immunol"},{"key":"R77-5-20210206","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody","volume":"182","author":"T\u00fcz\u00fcn","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R78-5-20210206","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0404.2007.00919.x","article-title":"Treatment of a patient with myasthenia gravis using antibodies against CD25","volume":"117","author":"Kakoulidou","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"R79-5-20210206","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clim.2008.03.509","article-title":"Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis","volume":"128","author":"Sheng","year":"2008","journal-title":"Clin Immunol"},{"key":"R80-5-20210206","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1196\/annals.1381.012","article-title":"DNA microarray in search of new drug targets for myasthenia gravis","volume":"1107","author":"Feferman","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"R81-5-20210206","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.4049\/jimmunol.180.4.2132","article-title":"Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis","volume":"180","author":"Aricha","year":"2008","journal-title":"J Immunol"},{"key":"R82-5-20210206","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2007.06.014","article-title":"Isolation and functional characterization of antiacetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture","volume":"189","author":"Sideris","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R83-5-20210206","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"issue":"Suppl","key":"R84-5-20210206","first-page":"81","article-title":"Antisense approach to anticholinesterase therapeutics","volume":"2","author":"Soreq","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"R85-5-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1196\/annals.1348.004","article-title":"Neuromuscular therapeutics by RNA-targeted suppression of ACHE gene expression","volume":"1082","author":"Dori","year":"2006","journal-title":"Ann N Y Acad Sci"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e328310da18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:04:45Z","timestamp":1786035885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-200811000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e328310da18","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}